MA48798B1 - OZANIMOD PRODUCTION PROCESS - Google Patents
OZANIMOD PRODUCTION PROCESSInfo
- Publication number
- MA48798B1 MA48798B1 MA48798A MA48798A MA48798B1 MA 48798 B1 MA48798 B1 MA 48798B1 MA 48798 A MA48798 A MA 48798A MA 48798 A MA48798 A MA 48798A MA 48798 B1 MA48798 B1 MA 48798B1
- Authority
- MA
- Morocco
- Prior art keywords
- ozanimod
- production process
- new
- polimop
- formula
- Prior art date
Links
- XRVDGNKRPOAQTN-FQEVSTJZSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 XRVDGNKRPOAQTN-FQEVSTJZSA-N 0.000 title abstract 3
- 229950008141 ozanimod Drugs 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
La présente invention concerne un nouveau procédé pour la préparation d'ozanimod de formule et de sels d'addition d'acide, par le biais de nouveaux intermédiaires et d'une nouvelle forme polimop à base d'ozanimod.The present invention relates to a new process for the preparation of ozanimod of formula and acid addition salts, through new intermediates and a new polimop form based on ozanimod.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP1700216 | 2017-05-22 | ||
PCT/HU2018/050019 WO2018215807A1 (en) | 2017-05-22 | 2018-05-18 | Process for the production of ozanimod |
Publications (2)
Publication Number | Publication Date |
---|---|
MA48798A MA48798A (en) | 2020-04-08 |
MA48798B1 true MA48798B1 (en) | 2023-10-31 |
Family
ID=89720175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA48798A MA48798B1 (en) | 2017-05-22 | 2018-05-18 | OZANIMOD PRODUCTION PROCESS |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200087269A1 (en) |
EP (1) | EP3630738B1 (en) |
CN (1) | CN110997645B (en) |
EA (1) | EA201992421A1 (en) |
ES (1) | ES2960051T3 (en) |
HR (1) | HRP20231308T1 (en) |
HU (1) | HUE064642T2 (en) |
MA (1) | MA48798B1 (en) |
PL (1) | PL3630738T3 (en) |
PT (1) | PT3630738T (en) |
SI (1) | SI3630738T1 (en) |
WO (1) | WO2018215807A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019094409A1 (en) * | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
US11390593B2 (en) | 2018-12-07 | 2022-07-19 | Synthon B.V. | Process for preparing ozanimod |
WO2020152718A1 (en) * | 2019-01-25 | 2020-07-30 | Mylan Laboratories Limited | Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile |
CN112062785B (en) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | Preparation method of ozagrel and intermediate thereof |
MX2022000651A (en) | 2019-07-16 | 2022-03-11 | Synthon Bv | Improved process for preparing ozanimod. |
CA3156298A1 (en) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
WO2021197852A1 (en) * | 2020-04-02 | 2021-10-07 | Synthon B.V. | Crystalline form of ozanimod hydrochloride |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA024801B1 (en) * | 2009-11-13 | 2016-10-31 | Рецептос Ллк | Selective sphingosine 1 phosphate receptor modulators |
CN106943407A (en) * | 2010-07-26 | 2017-07-14 | 赛诺菲 | Purposes of the Ben oxadiazole derivatives in the medicine for the treatment of allergia or inflammatory disease is prepared |
US20170165236A1 (en) * | 2013-11-01 | 2017-06-15 | Celgene International Ii Sàrl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
EP3470400A1 (en) * | 2016-06-14 | 2019-04-17 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of ozanimod, crystal form of hydrochloride thereof, and preparation method therefor |
WO2018033149A1 (en) * | 2016-08-19 | 2018-02-22 | 苏州科睿思制药有限公司 | Crystal forms of ozanimod and preparation method therefor |
WO2018049632A1 (en) * | 2016-09-14 | 2018-03-22 | 杭州领业医药科技有限公司 | Crystal form of ozanimod, and preparation method and pharmaceutical composition thereof |
CA3038106A1 (en) * | 2016-09-29 | 2018-04-05 | Celgene International Ii Sarl | Compounds and methods for treating lupus |
-
2018
- 2018-05-18 HU HUE18806925A patent/HUE064642T2/en unknown
- 2018-05-18 PT PT188069256T patent/PT3630738T/en unknown
- 2018-05-18 SI SI201831007T patent/SI3630738T1/en unknown
- 2018-05-18 EP EP18806925.6A patent/EP3630738B1/en active Active
- 2018-05-18 US US16/615,468 patent/US20200087269A1/en active Pending
- 2018-05-18 HR HRP20231308TT patent/HRP20231308T1/en unknown
- 2018-05-18 ES ES18806925T patent/ES2960051T3/en active Active
- 2018-05-18 EA EA201992421A patent/EA201992421A1/en unknown
- 2018-05-18 CN CN201880049683.6A patent/CN110997645B/en active Active
- 2018-05-18 MA MA48798A patent/MA48798B1/en unknown
- 2018-05-18 WO PCT/HU2018/050019 patent/WO2018215807A1/en unknown
- 2018-05-18 PL PL18806925.6T patent/PL3630738T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA48798A (en) | 2020-04-08 |
CN110997645B (en) | 2023-10-10 |
SI3630738T1 (en) | 2024-02-29 |
HRP20231308T1 (en) | 2024-04-26 |
ES2960051T3 (en) | 2024-02-29 |
PL3630738T3 (en) | 2024-04-08 |
WO2018215807A1 (en) | 2018-11-29 |
US20200087269A1 (en) | 2020-03-19 |
EP3630738A4 (en) | 2021-03-10 |
EA201992421A1 (en) | 2020-03-27 |
PT3630738T (en) | 2023-10-24 |
EP3630738A1 (en) | 2020-04-08 |
CN110997645A (en) | 2020-04-10 |
HUE064642T2 (en) | 2024-04-28 |
EP3630738B1 (en) | 2023-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA48798B1 (en) | OZANIMOD PRODUCTION PROCESS | |
FR3087439B1 (en) | Process for the preparation of 3α-hydroxy-5α-pregnan-20-one (brexanolone) | |
MA42678B1 (en) | NEW SUBSTITUTED NUCLEOSIDE ANALOGS WITH BICYCLIC AROMATIC CYCLE 6-6 FOR USE AS PRMT5 INHIBITORS | |
MA41607B1 (en) | Salts of a pi3k inhibitor and methods of preparing these salts | |
EA201690153A1 (en) | SUBSTITUTED PETROPHORANE AND BENZOXAZOLYL COMPOUNDS AND THEIR APPLICATIONS | |
MA38922A3 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors | |
MA42341A1 (en) | Protein kinase inhibitor, process for its preparation and medical use | |
MA34963B1 (en) | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | |
MA40480B1 (en) | Process for the crystallization of aripiprazole derivatives in sustained-release formulations for the treatment of schizophrenia | |
MA38330B1 (en) | Butanoic phosphonic acid derivatives of bisphenol substituted as nep inhibitors (neutral endopeptidase) | |
MX2017015662A (en) | Processes for the preparation of galnac acid derivatives. | |
NZ746906A (en) | Oxaborole esters and uses thereof | |
MX2020011671A (en) | A novel process for the preparation of anthranilic diamides. | |
PE20221420A1 (en) | PHOTOCHEMICAL PROCEDURE FOR THE PREPARATION OF (4R,4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAFTYRIDIN-3-CARBOXAMIDE | |
MA38250B1 (en) | New hydantoin derivatives for their uses in the treatment of diseases, such as osteoporosis and thrombocytopenia | |
BR112018070345A2 (en) | process for the preparation of 4-aminoindan derivatives and related aminoindan amides | |
MA41186B1 (en) | New crystal forms of foramsulfuron monosodium salt | |
FR3099478B1 (en) | Process for treating a composition comprising natural vanillin | |
FR3062851B1 (en) | PROCESS FOR THE MONOTOPE PREPARATION OF ORGANO-IODINE COMPOUNDS | |
MA38559B1 (en) | Imidazo-triazine derivatives used as pde10 inhibitors | |
FR3085036B1 (en) | VITAMIN A SYNTHESIS PROCESS | |
AR120727A1 (en) | PHARMACEUTICAL COMPOSITION THAT COMPRISES BPI-7711 AND METHOD OF PREPARATION OF THE SAME | |
MA50149B1 (en) | Process for the preparation of the piperazine ring for the synthesis of pyrazinocarbazole | |
BR112017014706A2 (en) | process for the production of condensed imidazole derivatives | |
MA35509B1 (en) | A process for synthesizing derivatives of 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one and application to the synthesis of ivabradine. |